MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57^Kip2 targeting

Published date: 15 December 2023

Additional Information: Funding Information: We would like to thank Maharshi Chakraborty, Richard Sallari (Axiotl Inc, Cleveland OH, USA) and Heike Wollmann (Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore), for technical and bioinformatics assistance. The Myogenin (Wright WE) and MHC (Fishman DA) antibodies were obtained from the Developmental Studies Hybridoma Bank, developed under the auspices of the NICHD and maintained by The University of Iowa, Department of Biology, Iowa City, IA 52242, USA. C.P. was supported by the Italian Ministry of University and Research (MIUR) Ph.D. fellowship (Department of Science, Roma Tre University Doctorate). We are very grateful to M. Dyer and E. Stewart from the Childhood Solid Tumor Network (CSTN) at St. Jude for PDX models used in this study. M.Co. was supported by a “Fondazione Veronesi” fellowship. This project has been funded by Associazione Italiana Ricerca sul Cancro (AIRC IG #10338, #15312 and #27794), Alleanza Contro il Cancro (ACC) Italian Network-Working Group Sarcomas, and Italian Ministry of Health Fondi 5xmille (2020-2021) and Current Research to R.R.; Alleanza Contro il Cancro (ACC) Italian Network-Working Group Sarcomas and Italian Ministry of Health Ricerca Finalizzata GR-2016-02364546 to B.D.A.; Italian Ministry of Health Ricerca Finalizzata GR-2013 02359212 to C.Q.; AIRC MFGA #22889 to E.V.; AIRC IG #24696 to F.M.; AIRC 5xmille (9962) to F.L. B.E.G. is supported through the DOD’s Convergent Science Virtual Cancer Center, Reign in Sarcoma, the V Foundation and Alex’s Lemonade Stand Foundation. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Funding Information: We would like to thank Maharshi Chakraborty, Richard Sallari (Axiotl Inc, Cleveland OH, USA) and Heike Wollmann (Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore), for technical and bioinformatics assistance. The Myogenin (Wright WE) and MHC (Fishman DA) antibodies were obtained from the Developmental Studies Hybridoma Bank, developed under the auspices of the NICHD and maintained by The University of Iowa, Department of Biology, Iowa City, IA 52242, USA. C.P. was supported by the Italian Ministry of University and Research (MIUR) Ph.D. fellowship (Department of Science, Roma Tre University Doctorate). We are very grateful to M. Dyer and E. Stewart from the Childhood Solid Tumor Network (CSTN) at St. Jude for PDX models used in this study. M.Co. was supported by a “Fondazione Veronesi” fellowship. This project has been funded by Associazione Italiana Ricerca sul Cancro (AIRC IG #10338, #15312 and #27794), Alleanza Contro il Cancro (ACC) Italian Network-Working Group Sarcomas, and Italian Ministry of Health Fondi 5xmille (2020-2021) and Current Research to R.R.; Alleanza Contro il Cancro (ACC) Italian Network-Working Group Sarcomas and Italian Ministry of Health Ricerca Finalizzata GR-2016-02364546 to B.D.A.; Italian Ministry of Health Ricerca Finalizzata GR-2013 02359212 to C.Q.; AIRC MFGA #22889 to E.V.; AIRC IG #24696 to F.M.; AIRC 5xmille (9962) to F.L. B.E.G. is supported through the DOD’s Convergent Science Virtual Cancer Center, Reign in Sarcoma, the V Foundation and Alex’s Lemonade Stand Foundation. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Publisher Copyright: © 2023, The Author(s).

Keywords: Carcinogenesis/genetics, Cell Line, Tumor, Child, Humans, Rhabdomyosarcoma/genetics, Transcription Factors

Local EPrints ID: 485866

URI: http://eprints.soton.ac.uk/id/eprint/485866

DOI: doi:10.1038/s41467-023-44130-0

ISSN: 2041-1723

PURE UUID: bed05144-be8e-4d2d-a614-c14aaf3dd5aa

ORCID for Zoë S. Walters: orcid.org/0000-0002-1835-5868

Date deposited: 03 Jan 2024 17:03

Last modified: 18 Mar 2024 03:43